{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:41:53Z","timestamp":1761896513518,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"PROgrama MULtidisciplinar para la Gesti\u00f3n de Antif\u00fangicos y la Reducci\u00f3n de Candidiasis Invasora (PROMULGA) II Project, Instituto de Salud Carlos III Madrid Spain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund (FEDER)","doi-asserted-by":"publisher","award":["PI13\/01148"],"award-info":[{"award-number":["PI13\/01148"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008061","name":"Fundacion Mutua Madrile\u00f1a","doi-asserted-by":"crossref","award":["FMM14\/13"],"award-info":[{"award-number":["FMM14\/13"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III Madrid Spain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund (FEDER)","doi-asserted-by":"publisher","award":["CM15\/00181"],"award-info":[{"award-number":["CM15\/00181"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.cmi.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T23:01:16Z","timestamp":1494630076000},"page":"1000.e1-1000.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Vena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"\u00c1lvarez-Ur\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gayoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mart\u00edn-Rabad\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cajuste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"G\u00f3mez Castell\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.05.006_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"De Pauw","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.05.006_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.05.006_bib3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.05.006_bib4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"Ecil recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic sct recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2017.05.006_bib5","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciu673","article-title":"Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis","volume":"59","author":"Duarte","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.05.006_bib6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3109\/10428191003682726","article-title":"Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies","volume":"51","author":"Hirata","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2017.05.006_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/14740338.2011.557062","article-title":"Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases","volume":"10","author":"Cornely","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2017.05.006_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2017.05.006_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 3\u20132009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2017.05.006_bib10","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/JCM.38.2.586-590.2000","article-title":"Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system","volume":"38","author":"Loeffler","year":"2000","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2017.05.006_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/mmy\/myu090","article-title":"Sputum and bronchial secretion samples are equally useful as bronchoalveolar lavage samples for the diagnosis of invasive pulmonary aspergillosis in selected patients","volume":"53","author":"Escribano","year":"2015","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2017.05.006_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.05.006_bib13","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"12","author":"Leeflang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2017.05.006_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cmi.2015.09.009","article-title":"Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis","volume":"22","author":"Springer","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.05.006_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.05.006_bib16","first-page":"496","article-title":"Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients","volume":"73","author":"Park","year":"2016","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2017.05.006_bib17","first-page":"30","article-title":"A\u00a0cohort study on breakthrough invasive fungal infections in high-risk patients\u00a0receiving antifungal prophylaxis","author":"Biehl","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17302616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17302616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:20:31Z","timestamp":1761117631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17302616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1198743X17302616"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.05.006","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}